

Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method of preparing a pharmaceutical composition for treating or inhibiting obesity, said method comprising:
identifying a compound which inhibits de novo lipogenesis in a mammal, wherein said compound is identified as a compound which inhibits de novo lipogenesis by measuring inhibitory activity of at least one candidate compound for inhibition of on carboanhydrase activity of at least one mammalian carboanhydrase,

selecting said candidate compound as a compound which inhibits de novo lipogenesis if said candidate compound exhibits inhibition of carboanhydrase activity of at least one mammalian carboanhydrase, and

incorporating said the selected compound which inhibits de novo lipogenesis with at least one conventional solid or liquid excipient or at least one conventional pharmaceutical auxiliary substance in a pharmaceutical composition for treating or inhibiting obesity.

2. (canceled).

3. (currently amended) [[A]] The method according to claim 1, wherein said at least one mammalian carboanhydrase comprises a mammalian carboanhydrase of subtype II or subtype V.

4. (canceled).